Kingsview Wealth Management LLC Has $14.65 Million Holdings in Johnson & Johnson $JNJ

Kingsview Wealth Management LLC boosted its holdings in Johnson & Johnson (NYSE:JNJ) by 26.2% in the 2nd quarter, Holdings Channel.com reports. The firm owned 95,885 shares of the company’s stock after acquiring an additional 19,909 shares during the period. Kingsview Wealth Management LLC’s holdings in Johnson & Johnson were worth $14,646,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds also recently made changes to their positions in JNJ. GFG Capital LLC acquired a new stake in Johnson & Johnson during the second quarter worth approximately $35,000. Stone House Investment Management LLC bought a new stake in shares of Johnson & Johnson during the 1st quarter valued at $47,000. 1248 Management LLC acquired a new stake in shares of Johnson & Johnson during the 1st quarter worth $48,000. Harvest Fund Management Co. Ltd bought a new position in shares of Johnson & Johnson in the first quarter worth $52,000. Finally, Pandora Wealth Inc. bought a new stake in Johnson & Johnson during the first quarter worth about $65,000. 69.55% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several equities analysts have commented on the stock. Wall Street Zen raised shares of Johnson & Johnson from a “hold” rating to a “buy” rating in a report on Saturday, September 13th. Wells Fargo & Company set a $212.00 price objective on shares of Johnson & Johnson and gave the company an “overweight” rating in a research report on Friday, October 3rd. Citigroup raised their target price on Johnson & Johnson from $213.00 to $215.00 and gave the company a “buy” rating in a report on Wednesday, October 15th. Sanford C. Bernstein boosted their price target on Johnson & Johnson from $172.00 to $193.00 and gave the stock a “market perform” rating in a report on Monday, October 6th. Finally, Raymond James Financial raised their price objective on Johnson & Johnson from $174.00 to $209.00 and gave the company an “outperform” rating in a research note on Wednesday, October 15th. Four equities research analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating and nine have given a Hold rating to the stock. According to data from MarketBeat.com, Johnson & Johnson currently has an average rating of “Moderate Buy” and an average price target of $201.05.

Johnson & Johnson Trading Up 0.4%

NYSE JNJ opened at $196.00 on Friday. The company has a market cap of $472.22 billion, a price-to-earnings ratio of 18.92, a price-to-earnings-growth ratio of 2.19 and a beta of 0.38. Johnson & Johnson has a twelve month low of $140.68 and a twelve month high of $197.18. The company has a quick ratio of 0.80, a current ratio of 1.07 and a debt-to-equity ratio of 0.50. The business’s fifty day moving average is $185.81 and its 200 day moving average is $170.04.

Johnson & Johnson (NYSE:JNJ) last posted its earnings results on Wednesday, August 30th. The company reported $2.26 EPS for the quarter. The firm had revenue of $24.02 billion during the quarter. Johnson & Johnson had a return on equity of 32.73% and a net margin of 27.26%. As a group, sell-side analysts expect that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, December 9th. Shareholders of record on Tuesday, November 25th will be given a $1.30 dividend. This represents a $5.20 annualized dividend and a yield of 2.7%. The ex-dividend date is Tuesday, November 25th. Johnson & Johnson’s dividend payout ratio is 50.19%.

Insider Activity at Johnson & Johnson

In other news, EVP Jennifer L. Taubert sold 56,471 shares of Johnson & Johnson stock in a transaction on Thursday, September 4th. The shares were sold at an average price of $177.81, for a total transaction of $10,041,108.51. Following the transaction, the executive vice president owned 178,013 shares in the company, valued at approximately $31,652,491.53. The trade was a 24.08% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 0.16% of the company’s stock.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.